SRRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SRRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Sierra Oncology's Total Assets for the quarter that ended in Mar. 2022 was $280.00 Mil.
During the past 12 months, Sierra Oncology's average Total Assets Growth Rate was 106.00% per year. During the past 3 years, the average Total Assets Growth Rate was 10.50% per year. During the past 5 years, the average Total Assets Growth Rate was 19.50% per year.
During the past 9 years, Sierra Oncology's highest 3-Year average Total Assets Growth Rate was 298.80%. The lowest was 9.70%. And the median was 16.70%.
Total Assets is connected with ROA %. Sierra Oncology's annualized ROA % for the quarter that ended in Mar. 2022 was -57.38%. Total Assets is also linked to Revenue through Asset Turnover. Sierra Oncology's Asset Turnover for the quarter that ended in Mar. 2022 was 0.00.
The historical data trend for Sierra Oncology's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sierra Oncology Annual Data | |||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | ||||||||||
Total Assets | Get a 7-Day Free Trial | 102.20 | 109.47 | 151.33 | 107.49 | 109.37 |
Sierra Oncology Quarterly Data | ||||||||||||||||||||
Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
Total Assets | Get a 7-Day Free Trial | 110.56 | 94.38 | 104.23 | 109.37 | 280.00 |
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Sierra Oncology's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as
Total Assets | = | Total Equity (A: Dec. 2021 ) | + | Total Liabilities (A: Dec. 2021 ) |
= | 95.998 | + | 13.369 | |
= | 109.37 |
Sierra Oncology's Total Assets for the quarter that ended in Mar. 2022 is calculated as
Total Assets | = | Total Equity (Q: Mar. 2022 ) | + | Total Liabilities (Q: Mar. 2022 ) |
= | 261.622 | + | 18.378 | |
= | 280.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sierra Oncology (NAS:SRRA) Total Assets Explanation
Total Assets is connected with ROA %.
Sierra Oncology's annualized ROA % for the quarter that ended in Mar. 2022 is
ROA % | = | Net Income (Q: Mar. 2022 ) | / | ( (Total Assets (Q: Dec. 2021 ) | + | Total Assets (Q: Mar. 2022 )) | / count ) |
= | -111.712 | / | ( (109.367 | + | 280) | / 2 ) | |
= | -111.712 | / | 194.6835 | ||||
= | -57.38 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2022) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Sierra Oncology's Asset Turnover for the quarter that ended in Mar. 2022 is
Asset Turnover | ||||||
= | Revenue (Q: Mar. 2022 ) | / | ( (Total Assets (Q: Dec. 2021 ) | + | Total Assets (Q: Mar. 2022 )) | / count ) |
= | 0 | / | ( (109.367 | + | 280) | / 2 ) |
= | 0 | / | 194.6835 | |||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of Sierra Oncology's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Vivo Opportunity Fund Holdings, L.p. | director, 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
William D. Turner | officer: Chief Reg & Tech Ops Officer | C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404 |
Mary Christina Thomson | officer: General Counsel | C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404 |
Joshua Richardson | director, 10 percent owner | C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025 |
Longitude Capital Partners Iii, Llc | 10 percent owner | 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
Longitude Prime Fund, L.p. | 10 percent owner | 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
Longitude Prime Partners, Llc | 10 percent owner | 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
Gaurav Aggarwal | director, 10 percent owner | C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025 |
Llp Abingworth | 10 percent owner | 38 JERMYN STREET, LONDON X0 SW1Y 6DN |
Vivo Opportunity Fund, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Andrew Sinclair | director | C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Craig A Collard | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Georgia Erbez | director | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Christy J. Oliger | director | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
From GuruFocus
By Business Wire Business Wire • 01-25-2022
By Business Wire Business Wire • 01-27-2022
By Business Wire Business Wire • 04-06-2022
By Business Wire Business Wire • 02-03-2022
By Business Wire Business Wire • 04-13-2022
By Business Wire Business Wire • 01-18-2022
By Business Wire Business Wire • 05-05-2022
By Business Wire Business Wire • 01-25-2022
By GuruFocus Research GuruFocus Editor • 11-11-2022
By Business Wire Business Wire • 01-27-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.